Pascal Touchon, Atara CEO
ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients
After more than two decades in the clinic, Atara Biotherapeutics’ T cell therapy tabelecleucel is finally headed to the FDA — but not without a pivotal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
